Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 2Suspended 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 9Tumor-Agnostic 6Gastrointestinal 4Head & Neck 3Gynecologic 3Thoracic 2Lymphoid 2Genitourinary 2Dermatologic 2Sarcoma 1Plasma cell 1CNS 1

Conditions

Ovarian Neoplasms 12Breast Neoplasms 10Endometrial Neoplasms 7Pancreatic Neoplasms 5Neoplasms 3Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Colorectal Neoplasms 3Carcinoma, Ovarian Epithelial 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Carcinoma, Renal Cell 2Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Neoplasms by Site 1Multiple Myeloma 1Melanoma 1Lymphoma 1Inflammation 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1

Interventions

Paclitaxel 28Carboplatin 28pembrolizumab 25Bevacizumab 14liposomal doxorubicin 12Cisplatin 11Gemcitabine 10Radiotherapy 8Drug Therapy 8Cyclophosphamide 8Blood Specimen Collection 8Topotecan 7Nivolumab 7olaparib 6Doxorubicin 6niraparib 5Therapeutics 5Dexamethasone 5pertuzumab 4pazopanib 4lenvatinib 4fludarabine 4cemiplimab 4atezolizumab 4Trastuzumab 4Surveys and Questionnaires 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Fulvestrant 4Docetaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × palbociclib × Gynecologic × Clear all
NCT05768139 2026-05-22

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT03065062 2026-02-13

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Suspended
75 enrolled
GastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms

NCT06307249 2024-03-12

PTST_PALBEVA

Lebanese University

Phase 1 Recruiting
50 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Inflammation, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡